News
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods.
In the video below, Androsavich explains how Ginkgo Datapoints generates data and provides it as a service to pharma ...
2d
Zacks Investment Research on MSNGinkgo Bioworks Holdings, Inc. (DNA) Stock Moves -1.94%: What You Should KnowThe most recent trading session ended with Ginkgo Bioworks Holdings, Inc. (DNA) standing at $8.09, reflecting a -1.94% shift from the previouse trading day's closing. This change was narrower than the ...
2don MSN
TIME magazine has released the list of the 100 Most Influential People of 2025 and Reshma Kewalramani, Indian-origin CEO, is ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Kewalramani becme the first female CEO of a large, public U.S. biotechnology company after immigrating from India at age 11 ...
This page features the latest news about the Ginkgo Bioworks stock. Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain ...
Trained in internal medicine and nephrology, Reshma once intended to teach, treat patients, and work in a lab after medical ...
From US president Donald Trump to Tesla CEO Elon Musk, Time Magazine's 100 Most Influential People of 2025 list included some ...
1d
ABP News on MSNNo Indian On TIME 100 Most Influential List For 2025, Barring THIS Indian-origin CEOWhile the list included new and old faces, there was not a single Indian to feature in the list. Last year, several Indian ...
3d
India Today on MSNWho is Reshma Kewalramani, the Indian-Origin biotech trailblazer on TIME's list?Born in Mumbai, Reshma moved to the United States in 1988. She pursued a career in medicine, earning her degree from Boston ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results